Cargando…

Peri-operative, functional and early oncologic outcomes of salvage robotic-assisted radical prostatectomy after high-intensity focused ultrasound partial ablation

BACKGROUND: Partial ablation of the prostate using high-intensity focussed ultrasound (HIFU-PA) is a treatment option for localised prostate cancer. When local recurrence occurs, salvage robot-assisted radical prostatectomy is a treatment option for selected patients, but there is a paucity of data...

Descripción completa

Detalles Bibliográficos
Autores principales: Thompson, James E., Sridhar, Ashwin N., Shaw, Greg, Rajan, Prabhakar, Mohammed, Anna, Briggs, Timothy P., Nathan, Senthil, Kelly, John D., Sooriakumaran, Prasanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7329479/
https://www.ncbi.nlm.nih.gov/pubmed/32611411
http://dx.doi.org/10.1186/s12894-020-00656-9
_version_ 1783552913244684288
author Thompson, James E.
Sridhar, Ashwin N.
Shaw, Greg
Rajan, Prabhakar
Mohammed, Anna
Briggs, Timothy P.
Nathan, Senthil
Kelly, John D.
Sooriakumaran, Prasanna
author_facet Thompson, James E.
Sridhar, Ashwin N.
Shaw, Greg
Rajan, Prabhakar
Mohammed, Anna
Briggs, Timothy P.
Nathan, Senthil
Kelly, John D.
Sooriakumaran, Prasanna
author_sort Thompson, James E.
collection PubMed
description BACKGROUND: Partial ablation of the prostate using high-intensity focussed ultrasound (HIFU-PA) is a treatment option for localised prostate cancer. When local recurrence occurs, salvage robot-assisted radical prostatectomy is a treatment option for selected patients, but there is a paucity of data on the peri-operative safety, functional and oncologic outcomes of sRARP.. The objective of this study was therefore to describe peri-operative safety, functional and early oncologic outcomes following salvage robot-assisted radical prostatectomy (sRARP) for local recurrence after HIFU-PA. METHODS: Retrospective analysis of a prospective database of 53 consecutive men who underwent sRARP after HIFU-PA from 2012 to 2018. Continence and erectile-function were reported pre-HIFU, pre-sRARP, 3-months post-sRARP and 12-months post-sRARP. Complications, PSMs and need for subsequent ADT/radiotherapy were assessed. RESULTS: 45 men were suitable for inclusion and had sufficient data for analyses. Median duration from HIFU to sRARP was 30.0 months and median follow-up post-sRARP was 17.7 months. Median age, PSA and ISUP group were 63.0 yrs., 7.2 ng/mL and 2; 88.9% were cT2. Median operative-console time, blood loss and hospital stay were 140 min, 200 ml and 1 day respectively. Clavien-Dindo grade 1, 2 and 3 complications < 90 days occurred in 8.9, 6.7 and 2.2%; late (>90d) complications occurred in 13.2%. At sRARP pathology, ISUP 3–5 occurred in 51.1%, pT3a/b in 64.5%, and PSMs in 44.4% (37.5% for pT2, 48.3% for pT3). Of men with > 3-months follow-up after sRARP, 26.3% underwent adjuvant radiotherapy/ADT for residual disease or adverse pathologic features; 5.3% experienced BCR requiring salvage ADT/radiotherapy. Freedom from ADT/radiotherapy was 66.7% at 12-months. Pad-free rates were 100% pre-HIFU, 95.3% post-HIFU, 29.4% 3-months post-sRARP, and 65.5% 12-months post-sRARP. Median IIEF-5 scores pre-HIFU, post-HIFU, 3- and 12-months post-sRARP were 23.5, 16, 5 and 5, respectively. Potency rates were 81.8, 65.5, 0 and 0%, respectively. Bilateral/unilateral nerve sparing were feasible in 7%/22%. CONCLUSION: Salvage RARP was safe with acceptable but sub-optimal continence and poor sexual-function and poor oncologic outcomes. One in three men required additional treatment within 12-months. This information may aid men and urologists with treatment selection and counselling regarding primary HIFU-PA vs primary RARP and when considering salvage RARP.
format Online
Article
Text
id pubmed-7329479
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-73294792020-07-02 Peri-operative, functional and early oncologic outcomes of salvage robotic-assisted radical prostatectomy after high-intensity focused ultrasound partial ablation Thompson, James E. Sridhar, Ashwin N. Shaw, Greg Rajan, Prabhakar Mohammed, Anna Briggs, Timothy P. Nathan, Senthil Kelly, John D. Sooriakumaran, Prasanna BMC Urol Research Article BACKGROUND: Partial ablation of the prostate using high-intensity focussed ultrasound (HIFU-PA) is a treatment option for localised prostate cancer. When local recurrence occurs, salvage robot-assisted radical prostatectomy is a treatment option for selected patients, but there is a paucity of data on the peri-operative safety, functional and oncologic outcomes of sRARP.. The objective of this study was therefore to describe peri-operative safety, functional and early oncologic outcomes following salvage robot-assisted radical prostatectomy (sRARP) for local recurrence after HIFU-PA. METHODS: Retrospective analysis of a prospective database of 53 consecutive men who underwent sRARP after HIFU-PA from 2012 to 2018. Continence and erectile-function were reported pre-HIFU, pre-sRARP, 3-months post-sRARP and 12-months post-sRARP. Complications, PSMs and need for subsequent ADT/radiotherapy were assessed. RESULTS: 45 men were suitable for inclusion and had sufficient data for analyses. Median duration from HIFU to sRARP was 30.0 months and median follow-up post-sRARP was 17.7 months. Median age, PSA and ISUP group were 63.0 yrs., 7.2 ng/mL and 2; 88.9% were cT2. Median operative-console time, blood loss and hospital stay were 140 min, 200 ml and 1 day respectively. Clavien-Dindo grade 1, 2 and 3 complications < 90 days occurred in 8.9, 6.7 and 2.2%; late (>90d) complications occurred in 13.2%. At sRARP pathology, ISUP 3–5 occurred in 51.1%, pT3a/b in 64.5%, and PSMs in 44.4% (37.5% for pT2, 48.3% for pT3). Of men with > 3-months follow-up after sRARP, 26.3% underwent adjuvant radiotherapy/ADT for residual disease or adverse pathologic features; 5.3% experienced BCR requiring salvage ADT/radiotherapy. Freedom from ADT/radiotherapy was 66.7% at 12-months. Pad-free rates were 100% pre-HIFU, 95.3% post-HIFU, 29.4% 3-months post-sRARP, and 65.5% 12-months post-sRARP. Median IIEF-5 scores pre-HIFU, post-HIFU, 3- and 12-months post-sRARP were 23.5, 16, 5 and 5, respectively. Potency rates were 81.8, 65.5, 0 and 0%, respectively. Bilateral/unilateral nerve sparing were feasible in 7%/22%. CONCLUSION: Salvage RARP was safe with acceptable but sub-optimal continence and poor sexual-function and poor oncologic outcomes. One in three men required additional treatment within 12-months. This information may aid men and urologists with treatment selection and counselling regarding primary HIFU-PA vs primary RARP and when considering salvage RARP. BioMed Central 2020-07-01 /pmc/articles/PMC7329479/ /pubmed/32611411 http://dx.doi.org/10.1186/s12894-020-00656-9 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Thompson, James E.
Sridhar, Ashwin N.
Shaw, Greg
Rajan, Prabhakar
Mohammed, Anna
Briggs, Timothy P.
Nathan, Senthil
Kelly, John D.
Sooriakumaran, Prasanna
Peri-operative, functional and early oncologic outcomes of salvage robotic-assisted radical prostatectomy after high-intensity focused ultrasound partial ablation
title Peri-operative, functional and early oncologic outcomes of salvage robotic-assisted radical prostatectomy after high-intensity focused ultrasound partial ablation
title_full Peri-operative, functional and early oncologic outcomes of salvage robotic-assisted radical prostatectomy after high-intensity focused ultrasound partial ablation
title_fullStr Peri-operative, functional and early oncologic outcomes of salvage robotic-assisted radical prostatectomy after high-intensity focused ultrasound partial ablation
title_full_unstemmed Peri-operative, functional and early oncologic outcomes of salvage robotic-assisted radical prostatectomy after high-intensity focused ultrasound partial ablation
title_short Peri-operative, functional and early oncologic outcomes of salvage robotic-assisted radical prostatectomy after high-intensity focused ultrasound partial ablation
title_sort peri-operative, functional and early oncologic outcomes of salvage robotic-assisted radical prostatectomy after high-intensity focused ultrasound partial ablation
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7329479/
https://www.ncbi.nlm.nih.gov/pubmed/32611411
http://dx.doi.org/10.1186/s12894-020-00656-9
work_keys_str_mv AT thompsonjamese perioperativefunctionalandearlyoncologicoutcomesofsalvageroboticassistedradicalprostatectomyafterhighintensityfocusedultrasoundpartialablation
AT sridharashwinn perioperativefunctionalandearlyoncologicoutcomesofsalvageroboticassistedradicalprostatectomyafterhighintensityfocusedultrasoundpartialablation
AT shawgreg perioperativefunctionalandearlyoncologicoutcomesofsalvageroboticassistedradicalprostatectomyafterhighintensityfocusedultrasoundpartialablation
AT rajanprabhakar perioperativefunctionalandearlyoncologicoutcomesofsalvageroboticassistedradicalprostatectomyafterhighintensityfocusedultrasoundpartialablation
AT mohammedanna perioperativefunctionalandearlyoncologicoutcomesofsalvageroboticassistedradicalprostatectomyafterhighintensityfocusedultrasoundpartialablation
AT briggstimothyp perioperativefunctionalandearlyoncologicoutcomesofsalvageroboticassistedradicalprostatectomyafterhighintensityfocusedultrasoundpartialablation
AT nathansenthil perioperativefunctionalandearlyoncologicoutcomesofsalvageroboticassistedradicalprostatectomyafterhighintensityfocusedultrasoundpartialablation
AT kellyjohnd perioperativefunctionalandearlyoncologicoutcomesofsalvageroboticassistedradicalprostatectomyafterhighintensityfocusedultrasoundpartialablation
AT sooriakumaranprasanna perioperativefunctionalandearlyoncologicoutcomesofsalvageroboticassistedradicalprostatectomyafterhighintensityfocusedultrasoundpartialablation